{
    "nctId": "NCT01781338",
    "briefTitle": "Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer",
    "officialTitle": "Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 4936,
    "primaryOutcomeMeasure": "Identification of a responder sub-population with intermediate and high risk, which due to therapy has outcome comparable to HR+/RS\u226411",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients, age at diagnosis 18 years and above (consider patients at 70 years and above for ADAPT Elderly)\n* Histologically confirmed unilateral primary invasive carcinoma of the breast\n* Clinical T1 - T4 (except inflammatory breast cancer)\n* All clinical N (cN)\n* No clinical evidence for distant metastasis (M0)\n* Known HR status and HER2 status (local pathology)\n* Tumor block available for central pathology review\n* Performance Status ECOG \\<= 1 or KI \\>= 80%\n* Negative pregnancy test (urine or serum) within 7 days prior to start of induction treatment in premenopausal patients\n* Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements\n* The patient must be accessible for treatment and follow-up\n\nExclusion Criteria:\n\n* Known hypersensitivity reaction to the compounds or incorporated substances\n* Prior malignancy with a disease-free survival of \\< 10 years, except curatively treated basalioma of the skin or pTis of the cervix uteri\n* Non-operable breast cancer including inflammatory breast cancer\n* Previous or concurrent treatment with cytotoxic agents for any reason after consultation with the sponsor\n* Concurrent treatment with other experimental drugs. Participation in another interventional clinical trial with or without any investigational not marketed drug within 30 days prior to study entry\n* Male breast cancer\n* Concurrent pregnancy; patients of childbearing potential must implement a highly effective (less than 1% failure rate) non-hormonal contraceptive measures during the study treatment\n* Breast feeding woman\n* Sequential breast cancer\n* Reasons indicating risk of poor compliance\n* Patients not able to consent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}